ASA and CAP rules shape what UK telehealth brands can credibly say about themselves, their products, and the conditions they treat. Most brands underestimate how strict the rules actually are — until an adjudication hits a paid campaign mid-flight. This piece is a structural overview of how the rules work, the common breaches, and how to build a pre-publication review process that prevents them.
Who ASA and CAP are and how they relate
ASA (Advertising Standards Authority) is the UK self-regulatory body enforcing the UK advertising codes. CAP (Committee of Advertising Practice) writes those codes. The CAP Code applies to non-broadcast UK advertising including digital, search, social, influencer, and direct mail. ASA adjudicates complaints and can publish naming adjudications against non-compliant advertisers.
The CAP Code rules that apply to UK pharma marketing (Rule 12)
CAP Code Rule 12 covers medicines, medical devices, health-related products, and beauty products. Rule 12.1 prohibits ads for medicinal products from appealing to children. Other clauses constrain efficacy claims, prescriber endorsements, and condition-led copy. Health and beauty advertising is one of the most-adjudicated areas of UK marketing.
Pre-broadcast clearance and Copy Advice
CAP Copy Advice is a free pre-publication service for advertisers. Submitting copy for advance review is the simplest way to avoid post-publication adjudication. The service is responsive and operators who use it consistently have notably lower breach rates. Pre-broadcast clearance applies to TV/cinema and uses different processes.
Most common breaches and how brands fall into them
The most common breaches are: condition-led copy implying guaranteed outcomes ('lose X kg', 'cure your ED'); influencer endorsement without proper disclosure; prescription-medicine naming in patient-facing ads; testimonial-based claims without substantiation; and comparative claims against competitors without evidence.
When ASA escalates to MHRA — and what that means
ASA and MHRA cooperate. Persistent or serious breaches involving prescription medicines can escalate from ASA adjudication to MHRA enforcement. MHRA enforcement carries financial and prosecutorial implications that ASA alone does not. Brands that ignore ASA adjudications increase their MHRA exposure substantially.
Building a pre-publication review process
A working pre-publication process has four parts. (1) Internal copy lead with documented authority. (2) Standard checklists per medium (social, paid search, influencer, email). (3) CAP Copy Advice for any campaign over a meaningful spend threshold. (4) An incident response process when an adjudication happens — fast removal beats slow defence.
Influencer disclosures must use #Ad or equivalent prominent labelling under ASA guidance. Reciprocal arrangements, gifted products, and affiliate links all trigger disclosure requirements.
The first time a regulator engages with you should not be in response to your launch campaign.
Marketing compliance is a discipline, not a one-off review. Brands that invest in pre-publication processes spend less in legal fees and lose fewer campaigns to mid-flight pulls. The discipline pays for itself.
